MetaCap

Entera Bio (ENTX) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iambic Therapeutics is the larger company by market cap ($621.4 million vs $575.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENTX+19.31%IAM-30.67%
+30%-10%-50%
Oct 15, 20261 yearNov 20, 2026
ENTX+23.32%IAM-44.94%
+27%-17%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENTX versus IAM key metrics
MetricENTXIAM
Share price$3.31$13.11
Market cap$575.53M$621.42M
1-day change+0.76%-8.06%
YTD return+70.36%—
1-year return+30.63%—
5-year return-3.64%—
EPS (TTM)$-0.40$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$42.00K—
Revenue growth (YoY)-76.80%—
Net income (latest FY)$-11.44M—
Gross margin0.00%—
Operating margin-27450.00%—
Net margin-27235.71%—
52-week high$4.20$25.00
52-week low$0.91$9.60
Distance from 52-week high-21.31%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+195.01%+107.86%
Average volume438.35K714.92K
Shares outstanding174.14M47.40M
Employees27171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Entera Bio

ENTX stock →

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

ENTX vs IAM FAQ

Which is bigger, Entera Bio or Iambic Therapeutics?

Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $575.53M for Entera Bio (ENTX).

Are Entera Bio and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons